GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (FRA:RMEA) » Definitions » Inventories, Inventories Adjustments
中文

ResMed (FRA:RMEA) Inventories, Inventories Adjustments

: €0 Mil (As of Dec. 2023)
View and export this data going back to 2012. Start your Free Trial

ResMed's Inventories, Inventories Adjustments for the quarter that ended in Dec. 2023 was €0 Mil.


ResMed Inventories, Inventories Adjustments Historical Data

The historical data trend for ResMed's Inventories, Inventories Adjustments can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Inventories, Inventories Adjustments
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ResMed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Inventories, Inventories Adjustments Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ResMed Inventories, Inventories Adjustments Calculation

Inventories, Inventories Adjustments represents certain charges made in the current period in inventory resulting from breakage, spoilage, employee theft and shoplifting, etc.


ResMed (FRA:RMEA) Business Description

Industry
Address
9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

ResMed (FRA:RMEA) Headlines

No Headlines